| |
Is your lab informatics platform science-aware™️? Many of today's LIMS and ELNs cannot flex without tedious coding or SQL. Read our guide and discover five key markers of a modern lab platform that drives productivity and simplifies life in the lab.
|
|
Today's Big NewsApr 27, 2023 |
| By Angus Liu In a surprise announcement Wednesday, Bristol Myers Squibb said CEO Giovanni Caforio will end his eight-year tenure and hand the baton to chief commercialization officer Chris Boerner. |
|
|
|
By Max Bayer The middle of Merck & Co.’s clinical batting order took center stage on the company’s first-quarter earnings call, including a phase 2 HIV combo therapy that once again returned to the lineup. |
By Angus Liu Bristol Myers Squibb is already juggling several important drug launches. But that doesn’t mean the company can’t take on another near-to-market asset now through an M&A deal, CEO Giovanni Caforio said. |
By Conor Hale CEO Michael Mussallem attributed part of the growth to improvements in healthcare hiring across several hospital departments, not just in the OR. |
|
Thursday, May 4, 2023 | 11am ET / 8am PT Join industry experts for this insightful webinar to learn more about enzyme inhibition studies. We’ll explore how these studies drive informed decisions for drug developers, frequently asked questions from sponsors, recommendations for achieving successful regulatory submission, and more. Register now.
|
|
By Annalee Armstrong Analysts are desperately trying to read the tea leaves comparing Eli Lilly’s Alzheimer’s med and Eisai/Biogen’s Leqembi before the mug is cool, but executives say there are “lots of ways for donanemab to win.” |
By Zoey Becker As AbbVie trudges through its long-dreaded year of biosimilar erosion to Humira, its longtime CEO is considering giving up the wheel. But such a move would only come after the dust settles, he said. |
By Nick Paul Taylor AstraZeneca has dumped a $855 million rare disease drug candidate after chalking up a pair of phase 2 flops, despite the prospect previously hitting the mark in a much larger phase 3 trial. The drugmaker disclosed the action alongside news of the jettisoning of a nonalcoholic steatohepatitis (NASH) therapy. |
By Kevin Dunleavy Recent moves by Merck—including last week’s $10.8 billion purchase of Prometheus Biosciences and its late-stage bowel disease candidate PRA023—have CEO Rob Davis thinking beyond the foreboding year of 2028. That's when the company expects to lose patent protection on cancer superstar Keytruda. |
By Conor Hale The clinical testing giant plans to acquire the Baltimore-based Haystack for its technology to detect minimal residual disease, by catching the early signs of a solid tumor’s recurrence by sifting out small pieces of cancer DNA floating in the bloodstream. |
By James Waldron A month after being abandoned by Biogen and Novartis in quick succession, Sangamo is now laying off around 120 employees as the genomic medicines biotech refocuses on three key areas. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we talk about how Pfizer became the first company in Big Pharma history with $100 billion in sales. We also dive into a J&J data leak, Eli Lilly's manufacturing spending plan and more of this week's top headlines. |
|
|---|
|
|
|
May 1 - 3, 2023 | Jersey City, NJ
Explore In-Depth Discussions Across 3 Tracks Dedicated to Medical Affairs Professionals. Last chance to register! Don’t miss out, register today.
|
|
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| WhitepaperHow can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| WhitepaperThe preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
| WhitepaperWe’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
| WhitepaperHow advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
